Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Ipilimumab in prostate cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune checkpoint inhibitors, such as ipilimumab , are a new class of immunotherapeutic agents that have shown significant efficacy in melanoma. A number of ongoing clinical trials are investigating the role of ipilimumab in prostate cancer, either alone or in combination with immunomodulating agents such as radiation and chemotherapy, and in combination with cancer vaccines.

          Related collections

          Author and article information

          Journal
          Expert Opin Biol Ther
          Expert opinion on biological therapy
          Informa Healthcare
          1744-7682
          1471-2598
          Feb 2013
          : 13
          : 2
          Affiliations
          [1 ] National Cancer Institute, National Institutes of Health, Center for Cancer Research, Medical Oncology Branch, Laboratory of Tumor Immunology and Biology, Bethesda, MD 20892, USA.
          10.1517/14712598.2012.754421
          23265575

          Comments

          Comment on this article